Lonza | LONN - Cash And Equivalent


Lonza reported CHF719M in Cash and Equivalent for its fiscal semester ending in December of 2025.





Cash And Equivalent Change Date
Akzo Nobel EUR 2.76B 1.14B Mar/2026
Alcon AG USD 1.58B 80M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
AstraZeneca USD 4.89B 2.67B Jun/2026
BASF EUR 7.8B 4.71B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
Beiersdorf EUR 1.2B 33M Dec/2025
Covestro EUR 648M 44M Dec/2025
Demant DKK 1.33B 188M Dec/2025
Fresenius EUR 2.06B 752M Mar/2026
Fresenius Medical Care EUR 1.06B 177.89M Jun/2026
Geberit CHF 403.6M 4.1M Mar/2025
Genmab DKK 1.5B 18M Jun/2026
Givaudan CHF 603M 3M Jun/2024
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GN Store Nord DKK 865M 254M Mar/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Johnson Matthey GBP 542M 49M Jun/2024
Merck EUR 2.74B 415M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Philips EUR 1.79B 803M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Sika AG CHF 1.87B 1.18B Dec/2022
Solvay EUR 367M 119M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024